Holen Sie sich die Stockscreener-App
10.37
1.47%
0.15
Handel nachbörslich:
10.37
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Analyst Calls: Does Phathom Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Safe Entry Momentum Tips - baoquankhu1.vn
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
Precision Trading with Phathom Pharmaceuticals Inc. (PHAT) Risk Zones - Stock Traders Daily
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
Tech Rally: Does Phathom Pharmaceuticals Inc have strong fundamentalsQuarterly Trade Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why - Bitget
Phathom Pharmaceuticals (PHAT) Is Up 10.0% After Guiding to 2026 Operating Profitability and Raising Capital - simplywall.st
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses - Yahoo Finance
Guggenheim Raises Price Target for Phathom Pharmaceuticals (PHAT) to $25 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Phathom Pharmaceuticals Hits Day High with 10.06% Surge in Stock Price - Markets Mojo
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Phathom stock price target to $25 on revenue beat - Investing.com Canada
Phathom Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-02-27 - Seeking Alpha
Phathom Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Phathom Pharma earnings beat by $0.34, revenue topped estimates - Investing.com Canada
Decoding Phathom Pharmaceuticals Inc (PHAT): A Strategic SWOT In - GuruFocus
Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative - simplywall.st
Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlig - GuruFocus
Stifel reiterates Buy on Phathom stock, keeps $28 price target By Investing.com - Investing.com Canada
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals (PHAT) Stock Analysis: A Look At Its 85.88% Potential Upside - DirectorsTalk Interviews
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 14.3% on Earnings Beat - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals Q4 2025 beats expectations, stock surges - Investing.com Nigeria
Phathom Pharmaceuticals Shares Rise After Q4 Loss Narrows, Revenue Rises - marketscreener.com
Phathom Q4 2025 slides: 217% revenue growth, profitability in sight By Investing.com - Investing.com UK
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.20 - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q4 Revenue $57.6M, vs. FactSet Est of $57.2M - marketscreener.com
PHATHOM PHARMA ($PHAT) Releases Q4 2025 Earnings - Quiver Quantitative
Phathom Pharmaceuticals : Fourth Quarter 2025 Earnings Call Presentation – February 2026 - marketscreener.com
Phathom Pharmaceuticals Q4 revenue slightly beats expectations - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals (PHAT) grows 2025 sales but remains deeply unprofitable - Stock Titan
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times
Phathom Pharmaceuticals Earnings Review: Q4 Summary - Benzinga
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million - TradingView
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
PHAT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 E - GuruFocus
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Biotech Phathom heads to Boston and Miami for investor talks in March - Stock Titan
Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6%Time to Sell? - MarketBeat
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? - MSN
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 - The Manila Times
Breakout Watch: Does Phathom Pharmaceuticals Inc have strong fundamentalsTrade Volume Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Trading the Move, Not the Narrative: (PHAT) Edition - Stock Traders Daily
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):